P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study
Authors: Zhixiao Wang, Min Yang, Jingdong Chao, Bruno Martins, Chien-Chia Chuang, Brad Shumel, Debra Sierka, Margaret Carboni, Bruce Strober
Journal: British Journal of Dermatology (2024)

Abstract Although atopic dermatitis (AD) typically affects children, it can persist into or start during adulthood. In the RELIEVE-AD study, which included adults with moderate-to-severe AD who initiated dupilumab in real-world clinical practice, results up to 3 years showed significant, sustained improvements in disease control, flares, skin symptoms, sleep, quality of life, and treatment satisfaction. We now report 4-year disease control, treatment satisfaction, and concomitant medication results from RELIEVE-AD. RELIEVE-AD is a single-arm, prospective, longitudinal patient survey study of adults with moderate-to-severe AD who were prescribed dupilumab, enrolled in the US dupilumab patient support programme. The patients had agreed to participate in online surveys at baseline and months 1, 2, 3, 6, 9, 12, 33–36 and 48. The outcomes presented here are (i) disease control [assessed by the six-item Atopic Dermatitis Control Tool (ADCT), with total score ranging from 0 to 24, with higher scores indicating less control, and score &amp;lt; 7 indicating controlled disease]; (ii) treatment satisfaction (seven-point Likert scale from ‘extremely satisfied’ to ‘extremely dissatisfied’) and (iii) reported days with no intense episodes of itching. Statistical significance was determined using generalized estimating equations to account for correlated data from the same patients. Among 698 patients who completed the baseline survey and started dupilumab, 353 (50.6%) completed the month 48 survey. At baseline, the mean age was 46.2 years, 61.7% were female, and common comorbidities included nonseasonal allergies (36.0%) and asthma (32.2%). The mean total ADCT score was significantly lower (P &amp;lt; 0.001) at all post-treatment initiation timepoints, decreasing from 15.8 at baseline to 3.7 at month 48. The proportion of patients with an ADCT total score &amp;lt; 7, indicating controlled disease, increased from 5.9% at baseline to 61.0% at month 1, then 77.4%, 80.7% and 80.5% at months 12, 33 and 48, respectively (all P &amp;lt; 0.001). The percentage of patients reporting no intense episodes of itching over the last week (0 days) increased from 3.2% at baseline to 61.2% at month 48 (P &amp;lt; 0.001). Patient satisfaction with AD treatments improved over time, with 84.9% of patients satisfied at month 48 (P &amp;lt; 0.001 for all timepoints during follow-up vs. baseline). A large majority of survey respondents at 4 years reported controlled disease, as well as fewer episodes of itching, and were very or extremely satisfied with their AD treatments. This research was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Medical writing and editorial assistance were provided by Rebecca Czolk, PhD, of Excerpta Medica, funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice guideline.